Drug intelligence / Profile preview

HDM2012

Development stage: Phase 1
Lead developer: Hangzhou Zhongmei Huadong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

HDM2012 is an oral small molecule inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1), currently under development by Huadong Medicine for the treatment of advanced solid tumors. HPK1 is a member of the MAP4K family and acts as a negative regulator of T-cell receptor (TCR) signaling. By inhibiting HPK1, HDM2012 aims to enhance T-cell activation and anti-tumor immune responses, potentially overcoming immunosuppression in the tumor microenvironment. It is being evaluated as a monotherapy and potentially in combination with other immunotherapies in Phase I clinical trials.

Other names: HDM-2012HDM2012HDM 2012

Targets

MAP4K1 (Hematopoietic progenitor kinase 1)

Beyond the preview

Go deeper on HDM2012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HDM2012.

Explore the full profile